8-K filing — NRX Pharmaceuticals, Inc. (NRXP)
Filed: 2026-10-16 AccNo: 0001437749-26-032828 Size: 174 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the
NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency